<DOC>
	<DOCNO>NCT00638612</DOCNO>
	<brief_summary>The purpose Phase 1 study evaluate safety potential efficacy Gene Mediated Cytotoxic Immunotherapy pancreatic cancer . The approach use adenoviral vector ( disabled virus ) engineer express Herpes thymidine kinase gene ( AdV-tk ) , follow antiherpetic prodrug , valacyclovir .</brief_summary>
	<brief_title>AdV-tk Therapy With Surgery Chemoradiation Pancreas Cancer ( PaTK01 )</brief_title>
	<detailed_description>The AdV-tk vector inject tumor tumor bed time biopsy standard tumor surgery valacyclovir pill take 14 day . Two course AdV-tk , follow valacyclovir , give adjuvant standard care therapy ( surgery and/or chemoradiation ) show work cooperatively AdV-tk kill tumor cell . Arm A resectable tumor first course give prior surgery second time surgery . Arm B locally advance disease AdV-tk injection administer needle injection tumor chemoradiation . The hypothesis combination therapy safely deliver lead improvement clinical outcome patient pancreatic cancer .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Must presume pancreatic adenocarcinoma base clinical radiologic evaluation identifiable tumor accessible injection ( pathologic diagnosis pancreatic adenocarcinoma must make prior AdVtk injection For Arm A , resectable disease . Arm B locally advance disease complete accrual . Performance status must ECOG 02 SGOT ( AST ) &lt; 3x upper limit normal Serum creatinine &lt; 2mg/dl calculated creatinine clearance &gt; 10ml/min Platelets &gt; 100,000/mm3 WBC &gt; 3000/mm3 ANC &gt; 1500/mm3 Must give study specific inform consent prior enrollment Primary hepatic dysfunction include active hepatitis exclude patient due obstructive jaundice . If obstructive jaundice clinically significant , bilirubin stable decrease prior enrollment . Evidence clinically significant pancreatitis determine investigator . Patients corticosteroid immunosuppressive drug Known HIV+ patient Patients acute infection ( viral , bacterial fungal infection require therapy ) Pregnant breastfeed patient . Female patient childbearing age must negative serum urine pregnancy test within 1 week begin therapy Evidence distant metastatic disease time enrollment malignancy ( except squamous basal cell skin cancer ) prior abdominal radiation therapy prior treatment pancreatic cancer Other serious comorbid illness compromise organ function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Cytotoxicity</keyword>
	<keyword>Tumor vaccine</keyword>
	<keyword>Radiation</keyword>
	<keyword>Surgery</keyword>
	<keyword>Chemoradiation</keyword>
</DOC>